Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

@article{Abraham2003EfficacyAS,
  title={Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.},
  author={Edward Abraham and Konrad A Reinhart and Steven M. Opal and Ignace Demeyer and Christopher Doig and Angel L{\'o}pez Rodriguez and Richard Beale and Petr Svoboda and Pierre François Laterre and Stuart Simon and Bruce Light and Herbert D M H Spapen and Judy Stone and Allan Seibert and Claus Peckelsen and Cathy S De Deyne and Russell Postier and Ville Pettil{\"a} and Charles L Sprung and Antonio Artigas and Sandra R. Percell and Vincent Shu and Christian Zwingelstein and Jeffrey Tobias and Lona Poole and James C. Stolzenbach and Abla A. Creasey},
  journal={JAMA},
  year={2003},
  volume={290 2},
  pages={238-47}
}
CONTEXT The expression and release of tissue factor is a major trigger for the activation of coagulation in patients with sepsis. Tissue factor pathway inhibitor (TFPI) forms a complex with tissue factor and blood protease factors leading to inhibition of thrombin generation and fibrin formation. OBJECTIVES To determine if administration of tifacogin… CONTINUE READING